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Four-hundred and nine parents of trial infants gave consent to participate in this nested study and 20
were included in the baseline assessment of their knowledge about trial participation. An additional 21 assessment was conducted approximately 90 days later, following completion of the clinical trial 22
protocol. 23
All parents received a Speaking Book at the start of the trial. Trial knowledge was already high at the 24 baseline assessment with no differences related to socio-economic status or education. Knowledge 25
of key trial information was retained at the completion of the study follow-up. The Speaking Book 26 (SB) was well received by the study participants. We hypothesize that the SB may have contributed 27 to the retention of information over the trial follow-up. Further studies evaluating the impact of this 28 innovative tool are thus warranted. 29 30 31
Keywords: Informed consent, knowledge, recall, decay, speaking book, Africa  32  33  34  35  36  37  38  39  40  41 Introduction  46 Individual agreement, or informed consent, is a process by which a potential participant voluntarily 47 confirms his or her willingness to participate in a clinical trial after having received necessary 48 information about all aspects relevant to inform this decision. This is a critical requirement for 49 participation in biomedical research and should include a demonstration of recall of the purpose of 50 the trial, potential benefits and harm, and participants' obligations and responsibilities. 1 The 51
informed consent process does not end at signing off the consent form, but continues throughout 52 the trial 2,3 and participants need to understand their rights including withdrawal at any time without 53 the need to give a reason for doing so. 54 55
When clinical trials are conducted in populations with low literacy levels, the process of informed 56 consent encounters several challenges related but not limited to the basic principles of autonomy, 57 voluntariness and comprehension. It is especially difficult for illiterate participants to appreciate how 58 clinical trials differ from medical care, since investigators perform research procedures with the 59 same medical instruments that are used in standard care. [4] [5] [6] The perceived authority of a physician 60 in these settings also often makes potential participants reluctant to ask questions or express 61 unwillingness to participate in the trial. 7 In addition, misunderstanding of trial procedures such as 62 randomization 8 are common. 63
There are particular challenges faced during the consent process in sub-Saharan Africa, given the 64 combination of low level of literacy in the population and high number of spoken rather than written 65 local languages. In many instances in these settings, the ICD is written in English or the 66 corresponding official language of the country and, for illiterate participants, it is verbally 67
interpreted by trained study staff during the consent process using their spoken language. 9 Consent 68 of illiterate participants is also supported by the presence of a literate impartial witness who should 69 be present throughout the discussion to attest that the information discussed is consistent with the 70 ICD and the process follows internationally acceptable ethical standards. The literate witness should 71 be independent of the trial and should read and translate any written information supplied to the 72 potential participant. 1 Identifying and recruiting independent, literate witnesses poses an additional 73 challenge. 74
75
In order to enable research participants to make an informed decision based on understanding of 76 consent information, a number of innovative techniques have been developed. These include use of 77 flower diagrams, flip charts with pictures, audio or audio-visual recordings and person-to-person 78 discussions amongst others. 3,10-13 Speaking Books (SB) have been developed to aid understanding 79 and recall of trial information in low literacy communities. The SB is A5 size, has hard covers and 80 large pages with each page of the book graphically illustrated with simple text relevant to the 81 illustration. Every SB also has a plastic panel with a built in battery, which hosts a series of push 82 buttons, each of which corresponds to a specific page in the speaking book. When activated, the 83 'push buttons' trigger a soundtrack of the text on the relevant page. The soundtrack is narrated by a 84 native speaker with the appropriate voice and tonal quality, and is thus vocalised to the person using 85 the book. 14 SB have been piloted among English speakers 14,15 but no study has examined their role 86 when provided in participants' local languages despite the fact that the book has been translated 87
into several local languages in Africa and Asia. 88 89
The nested study presented here assessed the recall of parents of infants participating in a 90 pneumococcal vaccine trial in a peri-urban setting in The Gambia, West Africa. This study was nested 91 within a phase III randomised, open-label trial aimed at evaluating the safety, tolerability and 92 immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) formulated in multi-dose 93 vials given with routine paediatric vaccinations in healthy infants (Idoko et al , under review, 94
Vaccine). The adult female literacy rate in this setting is about 30% 16 and health-seeking behaviour is 95 governed by traditions rather than modern health care norm. 17 We also assessed factors associated 96
with decay of knowledge of key information relating to the parent trial 18 during the three month 97 follow-up period employing a descriptive study design. The consent process for the parent trial 98 utilized the SB with information delivered in the main local languages in Western Gambia -Wollof 99
and Mandinka. 100
Results

101
Between January and May 2014, 500 infants were recruited for the parent trial. 428 parents (85.6%) 102
were approached for this nested study and 409 (95.6%) parents (all mothers in this case) gave oral 103 consent to answer the questions of the AQ in addition to the ACQ. The analysis was performed on 104 information available at the two time points assessed from 377 respondents (92.1%). 105 106
Most respondents were unemployed women (70.6%); 17.2% had no formal education, over 40% had 107 five or fewer years of formal education and approximately three quarters were in a monogamous 108
family (Table 1) , 109 110 111
For the 10 ACQ questions, over 99% of women during pre-trial assessment answered all of the 112 questions correctly at the first attempt and the remaining 1% at the second attempt. At the end of 113 the trial, all women responded correctly to the 10 questions in the only attempt given (Table 2) . 114
For the AQ, which was specific for the nested study, the frequency of correct answers was lower 115 with 6 out of 10 questions having less than 90% of correct answers pre-trial; and only 2 out of 10 116 post-trial. Questions with double negative statements like 'Your child will not receive other vaccines 117 for his/her age while in the study' were answered correctly by 71.1% of women pre-trial and 76.9% 118 post-trial compared to over 98% correct responses at both time points, for more straightforward 119 questions like 'You can request a form to take home and discuss with your family' (Table 2) . Overall, 120
the proportion of correct answers post-trial was higher than pre-trial, with significant differences for 121 "A malaria test will never be done if your child develops fever" (pre: 80.9% correct versus post: 122 94.7%, p<0.001); "the doctor will stop the study for your child if s/he thinks that your baby could be 123 hurt" (pre: 86.7% correct versus post: 97.3%, p<0.001) and "If your baby is unwell 5 days after 124 vaccination he/she must be admitted to hospital" (pre: 87.5% correct versus post: 99.6%, p<0.001). 125
No differences in level of trial knowledge were found by age, occupation, years of education, religion 126 or family type either at pre or post-trial (Table3). A difference between time points was only 127
observed as an increase in knowledge among farmers (from 75% to 90%), which was the group with 128 lowest knowledge pre-trial. This difference was however not statistically significant as the 129 confidence intervals at both time points overlapped and the 95% confidence interval for the mean 130 difference just crosses 0 (-30.2 -0.2) . 131 132
133
Participant responses to open ended questions 134 Most women (95.5%) did not recommend any change. Among those suggesting improvements 135 (multiple answers permitted), the most common suggestions were addition of other local languages 136 such as Fula, or Jola (2.7%); followed by increasing the speaker volume (0.8%), the need for extra 137 batteries (0.5%) and reduction in the size of the book (0.5%). 97.9% shared the book with other 138 family and friends. 139
The key messages stated by respondents to the open ended questions relating to their recall from 140 the SB are summarized as follows; 141
1) It provided a better recall of research ethics e.g. ["your child's confidential information will be 142 protected", "it is your decision to participate in the trial"]. 143
2) It provided a better recall of clinical research e.g. ["the field worker will visit for five days after 144 vaccination, "checking the blood is the most important part to me because without this it's 145
impossible to know what effect the vaccine has had"]. 146
3) It provided information on improving child health e.g. *"attending monthly maternal child health 147 clinics for vaccination can improve the health of your child"], 148
4) It explained the importance of vaccination e.g. *"I now understand why we take our children for 149 the monthly clinics and the importance of participating in research studies", "monthly vaccination is 150
important, can protect your child from diseases] 151
5) It stimulated interest in the trial e.g. [One 25year old respondent said "I listened to the book in my 152
neighbours' home and decided to come and find out more about the trial"]. 153 154
Discussion
155
In this study, we demonstrated that trial participants receiving a speaking book had a good 156 knowledge of the trial procedures at the start of the trial and retained this information during the 90 157 days of trial procedures. 158
Although trial information was generally well understood, the answers to more difficult questions, 159 such as those with double negative statements or related to clinical care, were less accurate (70-80% 160 correct answers compared to over 90%). This is probably a consequence of the generally low 161 educational levels in our study population. In both developed and developing country contexts it has 162 been shown that educational level was an independent predictor of comprehension. 19, 20 In contrast, 163 however, educational level was not associated with comprehension in our study as previously shown 164
in The Gambia, within a largely illiterate population. 21, 22 It may be that differences in education 165
within the study population are too lean to detect differences and is a subject for future research. 166
Interestingly, we noted that there was a trend of improvement of trial knowledge over the course of 167 the follow-up period for all age groups, occupations, educational levels, religions and family types. 168 We speculate that this trend (though not statistically significant) may, in part, have been due to the 169 use of the SB which encouraged continuous exposure to key trial information. 23 Our statement is 170 supported by the reports of high SB use and the sharing of the SB with other family members and 171 friends which implies continuous exposure to the trial information. Studies with comparator groups 172
where some participants do not receive the SB would however be necessary to confirm this 173 hypothesis as mere participation in the trial and other trial procedures could also account for this 174 trend. Previous studies which have assessed the use of multimedia tools 10,21 to assess recall of key 175 trial information one week after initial consent have also shown improvements in trial participants 176 knowledge of clinical trials, and their rights and responsibilities. Our study differs as the follow-up 177 period was longer (90 days) compared to the shorter follow-up of 1 week in other studies. 178 179
Most of the women appeared satisfied with the SB and did not suggest any improvements (95.5%). 180
Among suggested improvements were changes to portability of the book and increased battery life. 181
The suggestion to include other major oral languages in the SB, although ideal, it would be 182 impractical for logistical reasons due to the number of minor languages in the country. Still, in 183 countries with several local languages the limitation of the number of languages to be added to the 184 SB would always be a limitation to consider. We also observed that the SB is an additional tool for 185 expanding the information of an ongoing trial in the community, based on the responses of one of 186 our trial participants indicating that she first heard about our trial at a neighbors' home by listening 187 to her SB. 188 189
Beyond the limitations of the SB, this ancillary study has some limitations based on the study design, 190
given that all study participants had access to the SB prior to the assessment and thus there was no 191 comparator group to assess the real advantages of the book. We only included participants who had 192 passed the baseline assessment to the parent trial. We note however that only 2 out of 526 193 participants were excluded from the main trial for failing the baseline comprehension test. In The awareness of trial information was generally high in this illiterate population. 203
There was no apparent decay in consent information or change in recall in any of the 204 sociodemographic subgroups. 205
The SB has potential to educate low literacy communities regarding participation in clinical trials in 206 settings where written language translation is a challenge and may have benefits beyond education 207 for the specific trial. 208
Methods 209 210
Study design and population 211 212
The parent trial enrolled healthy infants aged 42 to 70 days weighing 3·5 kg or more who presented 213
for vaccination at Fajikunda Major Health Centre (FKHC), a government run health facility in western 214
Gambia that vaccinates approximately 5,000 children per year. Details of entry and exclusion criteria 215 are available at (ClinicalTrials.gov, NCT01964716). Children were recruited before the first dose of 216 PCV13 and were visited daily for 5 days after each vaccination to assess for local and systemic 217 adverse vaccine reactions, and seen monthly at the health facility until one month after the third 218 dose of PCV13. Parents who gave consent for their infants to participate in the trial were 219 approached to participate in this descriptive nested study. 220 221 222
Consent process 223 224
Community leaders including household heads, women and youth leaders and local religious leaders 225
were visited to give information regarding the trial. This was followed by large community 226 sensitisation meetings at which the trial team explained key trial information and addressed 227 concerns raised on the cultural and social appropriateness of some of the trial procedures such as 228 frequency of appointments and what each clinic/home visit would entail. 229 230
The trial staff subsequently approached potential participants at the Infant Welfare clinic located 231 within FKHC, and held discussions about the parent trial with parents who brought their infants for 232 routine immunisations/care. The parents were encouraged to seek clarity on any aspect of the 233 parent trial. The trial staff then asked the parent a set of questions to ensure understanding, and 234 provided a copy of the ICD to be taken home to discuss with other family members. These steps are 235 in accordance with the routine consent process for trials of this nature in this setting. 236 237
Following this, meetings to discuss the contents of the ICD and answer any questions from other 238 family members identified by the parent were arranged. Individuals who continued to express 239 willingness to participate in the study received a copy of the SB as required by the parent trial. The 240
SB was developed in two major Gambian languages: -Mandinka and Wolof. The book explained in 241 clear local dialect the basic elements of the trial participation including trial purpose, participant 242 rights, and their roles and responsibilities (Figure 1) . The research staff further explained to parents 243 who gave consent how to use the book, including how to switch between the two local language 244 recordings. 245
Parents were then requested to visit the FKHC for informed consent procedure (including another 246 explanation of the consent document and an opportunity to ask questions). Assessment of eligibility 247 was also performed by the trial clinicians during this visit. Consent information was given only in 248
Mandinka, Wolof or English, based on participant preference. 249
250
Following these procedures, participant recall of key trial information was assessed using an 251
interviewer-administered Assessment of Consent recall Questionnaire (ACQ). 252 253
The ACQ was a 10-item questionnaire with a 'true' or 'false' response. Domains covered by this 254 questionnaire included purpose of the trial, confidentiality, voluntariness and trial procedures. A 255 score of 1 was assigned for each question answered correctly and 0 for questions answered 256
incorrectly. If the total score was 10 the participant was enrolled. If the score was 9, the question 257 wrongly answered was reviewed with the parent and the participant enrolled. A score of 8 or below 258 required a review of trial information followed by a second attempt at the ACQ. If any error was 259 made at the second attempt, the participant was not eligible for enrolment into the parent trial. 260 261
Parents of infants recruited in the parent trial were subsequently approached to participate in this 262
nested study by giving oral consent. Where consent was given, an Additional Questionnaire (AQ) 263 comprising of 10 question items (8 true or false and two open ended) was then administered on the 264 day of enrolment) asking more in-depth questions regarding the trial. Only one attempt was allowed 265 to respond at these questions and the results did not compromise the participation in the parent 266 trial. Additional questions on experience of use of the SB were asked post trial (90 days post 267 enrolment) along with the re-administration of the ACQ and AQ. 268 269
The knowledge of informed consent information was determined by the responses to questions in 270 the two questionnaires.
272
This study utilized a speaking book narrated in the well known voice of a popular local media 273 personality. 274 275 276
Statistical methods 277 278
Statistical analysis 279 280
Data analysis 281 Twenty items from both questionnaires were used to assess the knowledge of participants, 282 estimated by the proportion of correct responses given by the participants. Socio-demographic 283 factors (age, education level, religion, family type and occupation) and each knowledge assessment 284 item, all categorical, were summarized by proportion. Fisher's exact tests for association were 285 applied to compare the proportions of correct answers for each item between visits. 286 Further, ordinary least square (OLS) linear regression analysis was applied to estimate and compare 287 mean proportions of correct answers (with their 95% confidence intervals) between and within 288 different levels of socio-demographic factors. Separate analyses were conducted at the two time 289
points and for the paired differences between the two visits (knowledge decay). Overall p values of 290 associations were estimated for the outcomes (visit one and visit four), as well as specific p values 291
for within socio-demographic group knowledge decay. 292
All analyses were conducted in Stata version 12 (StataCorp, USA). A two-sided p value <0.05 was 293 considered to be statistically significant. 294
Open ended questions were analyzed through content analysis of participant responses 18 . 295
296
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Health centre The Gambia who hosted the study and the study communities and participants. 2 (0.5%) 0 (0.0%) 1 teaspoon of blood will be collected from your child at the 4 th visit. (attempts) 0.50 1 375 (99.5%) 377 (100.0%) 2 2 (0.5%) 0 (0.0%) You are free to withdraw from this study at any time. (attempts) 0.50 1 375 (99.5%) 377 (100.0%) 2 2 (0.5%) 0 (0.0%) Study nurses can tell anyone about your participation in the study (attempts) 0.50 1 375 (99.5%) 377 (100.0%) 2 2 (0.5%) 0 (0.0%) You will be visited by a field worker for 5 days after each vaccination (attempts) 0.50 1 375 (99.5%) 377 (100.0%) 2 2 (0.5%) 0 (0.0%) Your child's participation in the study will be for a period of 4 months (attempts) 0.50 1 375 (99.5%) 377 (100.0%) 2 2 (0.5%) 0 (0.0%)
Additional questions to assess consent recall and decay (AQ)
Vaccines will help to protect your child against getting diseases caused by germs. 
